{"filing":{"accession_number":"0001628280-26-054288","cik":"0000834365","ticker":"BLFS","company_name":"BIOLIFE SOLUTIONS INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"blfs-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/834365/000162828026054288/blfs-20260806.htm"},"events":[{"id":25889,"run_id":23504,"accession_number":"0001628280-26-054288","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"BioLife Solutions issued a press release on August 6, 2026 announcing unaudited financial results for Q2 2026 and the six-month period ended June 30, 2026. The disclosure includes detailed revenue ($28.5M, up 21% YoY), gross margin (64% GAAP, 65% adjusted), operating income, net income ($45.1M including a $42.4M non-cash tax benefit), and adjusted EBITDA metrics. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, the designated Item for results of operations and financial condition.","company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26823,"accession_number":"0001628280-26-054288","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioLife Solutions issued a press release on August 6, 2026 announcing unaudited financial results for Q2 2026 and the six-month period ended June 30, 2026. The disclosure includes detailed revenue ($28.5M, up 21% YoY), gross margin (64% GAAP, 65% adjusted), operating income, net income ($45.1M including a $42.4M non-cash tax benefit), and adjusted EBITDA metrics. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, the designated Item for results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:41:14.341658+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26823,"accession_number":"0001628280-26-054288","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioLife Solutions issued a press release on August 6, 2026 announcing unaudited financial results for Q2 2026 and the six-month period ended June 30, 2026. The disclosure includes detailed revenue ($28.5M, up 21% YoY), gross margin (64% GAAP, 65% adjusted), operating income, net income ($45.1M including a $42.4M non-cash tax benefit), and adjusted EBITDA metrics. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, the designated Item for results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:41:14.341658+00:00","company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","filing_date":"2026-08-06"}]}